EGFRvIII immunogen and methods for using same

Patent metadata

Field	Value
Publication number	US-11530242-B2
Application number	US-201917259400-A
Country	US
Kind code	B2
Filing date	Jul 16, 2019
Priority date	Jul 17, 2018
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

An immunogen includes an antigenic EGFRvIII peptide linked to a Qβ bacteriophage virus-like particle (VLP) carrier. The antigenic EGFRvIII peptide has at least 53%, at least 61%, at least 69%, at least 76%, at least 84%, or at least 92% sequence similarity amino acid similarity to LEEKKGNYVVTDH (SEQ ID NO:1).

First claim

What is claimed is:

1. An immunogen comprising:
an immunogenic carrier comprising a Qβ bacteriophage virus-like particle (VLP); and
an antigenic EGFRvIII peptide comprising LEEKKGNYVVTDH (SEQ ID NO:1) linked to the immunogenic carrier.

2. The immunogen of claim 1 , wherein the immunogenic carrier is linked to the EGFRvIII peptide through a succinimidyl-6-[β-maleimidopropionamido]hexanoate (SMPH) cross-linker molecule.

3. A composition comprising the immunogen of claim 1 .

4. An immunogenic composition comprising the immunogen of claim 1 and at least one adjuvant.

5. A method of treating cancer in an individual, the method comprising administering a therapeutically effective amount of an immunogen to the individual, the immunogen comprising:
an immunogenic carrier comprising a Qβ bacteriophage virus-like particle (VLP); and
an antigenic EGFRvIII peptide comprising LEEKKGNYVVTDH (SEQ ID NO:1) linked to the immunogenic carrier.

6. The method of claim 5 , wherein the method further comprises administering to the individual at least one additional therapeutic agent for treating the cancer.

7. A nucleic acid encoding the immunogen of claim 1 .

8. An expression vector comprising the nucleic acid of claim 7 .

9. A host cell comprising the expression vector of claim 8 .

Assignees

• Unm Rainforest Innovations
• Chackerian Bryce
• Rixe Oliver

Inventors

• Chackerian Bryce
• Rixe Oliver

Classifications

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/6075

  Viral proteins · CPC title

• C12N2795/18123

  Virus like particles [VLP] · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K14/71

  for growth factors; for growth regulators · CPC title